Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2021 07:00 ET | Source: MatriSys Bioscience

MatriSys Announces Positive Results from a Study of S. felis for the Treatment of Drug-resistant S. pseudintermedius

LA JOLLA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced the publication of research on...
July 29, 2021 07:00 ET | Source: MatriSys Bioscience

MatriSys Bioscience to Present at the 4th Microbiome Movement Skin Health & Dermatology Summit

LA JOLLA, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that the company’s CEO,...
March 25, 2021 07:00 ET | Source: MatriSys Bioscience

MatriSys Bioscience Names Joyce Rico as Chief Medical Officer

LA JOLLA, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced the hiring of Joyce Rico, MD,...
March 18, 2021 07:00 ET | Source: MatriSys Bioscience

MatriSys Bioscience Expands Licensing Agreement with UCSD School of Medicine to Develop Acne Treatment

LA JOLLA, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that the company has licensed...
March 11, 2021 07:00 ET | Source: MatriSys Bioscience

MatriSys Bioscience Raises more than $3 million to Advance its Portfolio of Products to Treat Inflammatory Skin Diseases

LA JOLLA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced that it has raised more than...
February 22, 2021 14:07 ET | Source: MatriSys Bioscience

MatriSys Announces Positive Results From a Phase I Study of MSB-0221 for the Topical Treatment of Atopic Dermatitis

- Study Reveals the Potential of Beneficial Bacteria to Treat Chronic Skin Diseases - LA JOLLA, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial...
May 28, 2020 14:11 ET | Source: MatriSys Bioscience

MatriSys Bioscience Inc. is pleased to announce that we have been selected as a CONNECT 2020 Cool Company

SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics is pleased to announce that it was named a 2020 “Cool Company” by...
May 26, 2020 12:25 ET | Source: MatriSys Bioscience

MatriSys Bioscience Inc. is pleased to announce that Magda Marquet PhD has been appointed Chairwoman of MatriSys’ Board of Directors

SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics, is pleased to announce that Magda Marquet PhD has been appointed...
May 19, 2020 03:09 ET | Source: MatriSys Bioscience

MatriSys Bioscience is pleased to announce the appointment of Dr. James Mackay to its Board of Directors

SAN DIEGO, May 19, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the...
March 20, 2019 19:55 ET | Source: MatriSys Bioscience

MatriSys Bioscience announces successful FDA Pre-IND review and Phase 2 plans for MSB-01, a revolutionary human-microbiome based treatment for Atopic Dermatitis

SAN DIEGO, March 20, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a clinical stage biotechnology company developing rationally designed microbiome therapeutics to treat the top five skin...

Next Page keyboard_arrow_right